Context Therapeutics Inc.
HealthcareNASDAQ:CNTX · NASDAQ Capital Market
-$0.03 today
Vol 0.50M · Avg 0.80M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$36.1M -35.2% | -$26.7M -11.5% | -$24.0M -61.5% | -$14.8M -41.9% | -$10.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $16.3K +49.4% | $10.9K -9.7% | $12.0K +30.0% | $9.3K | $0 | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $1.3M +58.1% | $841.9K -21.8% | $1.1M +10.3% | $976.4K +91.1% | $511.1K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $6.3M +280.7% | -$3.5M -295.8% | $1.8M +739.8% | -$277.5K +87.5% | -$2.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $1.1M +215.9% | -$946.0K -165.4% | $1.4M +283.6% | -$787.9K +9.0% | -$866.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $5.2M +305.0% | -$2.5M -868.9% | $329.0K -35.5% | $510.4K +137.6% | -$1.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $2.1M -85.7% | $14.8M +28364.7% | $52.0K -91.0% | $578.5K -82.8% | $3.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$26.4M -81.3% | -$14.6M +30.8% | -$21.0M -55.3% | -$13.5M -54.0% | -$8.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$33.9K +99.8% | -$14.8M | $0 +100.0% | -$536.8K -114.7% | -$250.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$2.0M +86.4% | -$14.7M | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$2.0M +86.2% | -$14.8M | $0 +100.0% | -$536.8K -114.7% | -$250.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | -$15.3K -100.0% | $109.3M | $0 +100.0% | -$102.1K -100.2% | $53.4M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 | $0 | $0 | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$15.3K -100.0% | $109.3M | $0 +100.0% | -$102.1K -100.2% | $58.4M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 -100.0% | $50.4K | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$28.4M -135.6% | $80.0M +480.0% | -$21.0M -48.9% | -$14.1M -128.7% | $49.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$26.4M +9.9% | -$29.3M -39.3% | -$21.0M -49.4% | -$14.1M -55.7% | -$9.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Clene Inc.
NASDAQ:CLNN
$60.20M
SEC Filings
Recent regulatory filings
No filings found.
Does CNTX generate free cash flow?
Context Therapeutics Inc. (CNTX) generated -$26,419,330.00 of free cash flow in fiscal 2025.
How much operating cash flow does CNTX produce?
Operating cash flow was -$26,385,380.00, before capital expenditures of $33,948.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.